Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Eukaryotic Gene Expression
Impact-faktor: 2.156 5-jähriger Impact-Faktor: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Druckformat: 1045-4403
ISSN Online: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2015014360
pages 299-305

Advances in Molecular Biomarkers for Gastric Cancer

Tang-Hui Zheng
Department of Gastroenterology, Zhongshan Hospital affiliated with Xiamen University, 201 Hubin South Rd., Xiamen 361004, Fujian Province, China; Union Clinical Medical College of Fujian Medical University, Fuzhou 350001, Fujian Province, China
Jun-Lin Zhao
Department of Anesthesiology, First Affiliated Hospital to Xiamen University, Xiamen, Fujian Province, China
Bayasi Guleng
Department of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian Province, China; Medical College of Xiamen University, Xiamen, Fujian Province, China, 361005

ABSTRAKT

Gastric cancer (GC) is the second most frequent oncological cause of death, the fifth most common malignancy in the world, and accounts for 6.8% of all tumors. As an aggressive disease, GC is often diagnosed at an advanced stage, which is why it is a major cause of cancer-related death. In the last several decades, the incidence of GC has decreased, which should be credited to advances in diagnostic and therapeutic technologies including tumor-marker detection systems, imaging modalities, pathological methods, gastroscopy, and particularly surgical and pharmacologic interventions. Because they are economical, convenient, and noninvasive, the detection of conventional serum tumor biomarkers (e.g., CEA, CA19-9, and CA72-4) has been widely employed in the diagnosis and evaluation of GC. However, due to their poor specificity and sensitivity, these molecular markers cannot meet the demand of early GC detection. Hence, new and reliable tumor biomarkers are desperately needed. This review systematically summarizes the three most commonly used biomarkers of GC (e.g., CEA, CA19-9, and CA72-4) and addresses two categories of potential molecular biomarkers for the diagnosis of GC: microRNA and methylated DNA.


Articles with similar content:

Liquid Biopsies for Assessing Metastatic Melanoma Progression
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Dave S.B. Hoon, Kelly Huynh
The Adenoma-Carcinoma Sequence and Prospects for the Prevention of Colorectal Neoplasia
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 5-6
Julian Little, Seonaidh Cotton, Linda Sharp
DNA Fingerprint Technology: Its Application in Detecting Pancreatic Cancer
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Gayathri Chalikonda, Bhaskar V. K. S. Lakkakula, Neha Merchant, Ganji Purnachandra Nagaraju
Prognostic and Predictive Role of Raf Kinase Inhibitor Protein (RKIP) Within the RAS/ MAP Signaling Pathway in Colorectal Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 2
A. Lugli, P. Minoo, I. Zlobec
Genomic Pathology and Biomarkers in Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Ping Tang, Zhang Zhang